No Data
AIM Vaccine Gets Marketing Approval From China's NMPA After Phase III Trials Completion
Aimei's 13-valent pneumonia vaccine has obtained the corresponding production license and has officially submitted the market registration.
Hong Kong healthcare stocks continue to attract attention from investors, with AstraZeneca's another super heavyweight large single product set to be listed soon.
On November 1st, the company announced that the 13-valent combined pneumonia vaccine independently developed by the company has been submitted to the National Medical Products Administration for pharmaceutical marketing registration. The results of the completed Phase III clinical trial, showing that the vaccine has good immunogenicity and safety, have met the clinical pre-set goals. The group's wholly-owned subsidiary, EM Pharmaceutical Co., Ltd., has obtained the corresponding pharmaceutical production license for producing this product.
Amy pneumonia vaccine: The 13-valent combined pneumonia vaccine has obtained the corresponding production license, has been submitted for market registration, and the super heavyweight product is entering the harvest period.
Aimee Vaccine Announcement, the company's independently developed 13-valent pneumonia vaccine was submitted for pharmaceutical registration to the National Medical Products Administration on October 31. Before the COVID-19 pandemic, the 13-valent pneumonia vaccine was the global vaccine sales champion for ten consecutive years. Aimee's super heavyweight l is entering the countdown to market listing. According to the announcement, the results of the Phase III clinical trial with unblinded data show that Aimee's 13-valent pneumonia vaccine has good immunogenicity and safety, achieving the clinical preset goals. In addition, the group's wholly-owned subsidiary Aimee Biopharmaceutical Co., Ltd. has obtained the corresponding pharmaceutical production license for manufacturing this product.
Sino Biopharmaceutical (06660) has obtained the corresponding production license for 13-valent pneumococcal conjugate vaccine, submitted for market registration, and the bottom transaction has hit a historic new high.
According to the Securities Times app, Amy Vaccine (06660) announced that the company's independently developed 13-valent combined pneumonia vaccine has been submitted to the National Pharmaceuticals and Food and Drug Administration...
AIM Vaccine Unit's RSV Drug Approved by NMPA for Clinical Trials
No Data
No Data